Recombinant Human Prostacyclin receptor (PTGIR)

What is the Prostacyclin receptor (PTGIR) and what cellular systems express it?

The Prostacyclin receptor (PTGIR) is a member of the G protein-coupled receptor family 1 that serves as the receptor for prostacyclin (prostaglandin I2 or PGI2) . PTGIR couples to Gαs proteins and, upon activation by its ligand PGI2, stimulates adenylate cyclase to convert GTP into cyclic AMP (cAMP) . This receptor plays critical roles in multiple physiological systems, particularly in vascular tissues where it mediates vasodilation and inhibits platelet aggregation . PTGIR is expressed in vascular endothelium, platelets, and various immune cells, with expression levels varying significantly across tissue types.

How does PTGIR signaling affect downstream molecular pathways?

PTGIR signaling primarily operates through a Gαs-coupled pathway that activates adenylyl cyclase, leading to cAMP production and subsequent protein kinase A (PKA) activation . This activation cascade stimulates the activity of multiple transcription factors including CtBP1, SPI1, and STAT3 through phosphorylation mechanisms . Notably, PTGIR signaling has been demonstrated to control the expression of S100A8 and S100A9 genes, which encode the two subunits of calprotectin (CP) . This regulatory pathway appears to be dependent on adenylate cyclase and STAT3 signaling, linking prostaglandin signaling to inflammatory responses.

What physiological functions does PTGIR modulate?

PTGIR modulates several critical physiological functions:

• Cardiovascular regulation: Mediates vasodilation and inhibits platelet aggregation, contributing to vascular homeostasis

• Nociception: Participates in pain perception pathways, particularly in inflammatory contexts

• Inflammation: Regulates inflammatory processes through its effects on immune cell function and inflammatory mediator production

• Gene expression: Controls the expression of inflammatory proteins, particularly calprotectin, through cAMP-dependent transcriptional regulation

The diverse functions of PTGIR make it a compelling target for research across multiple disease areas, particularly in conditions with inflammatory or vascular components.

What selective antagonists are available for PTGIR research, and how do they differ?

Two structurally distinct series of selective IP receptor antagonists have been developed for research applications: RO1138452 and RO3244794 . These compounds display different pharmacological profiles while both maintaining high affinity for the IP receptor.

Table 1: Comparative Properties of PTGIR Antagonists

Both antagonists have demonstrated efficacy in reducing pain responses in experimental models, including acetic acid-induced abdominal constrictions and carrageenan-induced mechanical hyperalgesia and edema formation . RO3244794 additionally reduced chronic joint discomfort in models of monoiodoacetate-induced arthritis . The higher selectivity of RO3244794 makes it particularly valuable for studies requiring minimal off-target effects.

How does PTGIR regulate calprotectin expression, and what are the implications for inflammatory disease research?

Recent functional genomics research has established a direct link between PTGIR signaling and the expression of calprotectin, an important inflammatory biomarker . Specifically:

• Increasing PTGIR expression or stimulating PTGIR signaling with agonists like Beraprost significantly upregulates S100A8 and S100A9 gene expression (fold change = 6.25 and 6.85 respectively, p < 0.001)

• Conversely, knockdown of PTGIR or treatment with the antagonist RO1138452 decreases S100A8 and S100A9 expression (fold change = 0.46 and 0.48 respectively, p < 0.01)

• This regulatory pathway operates through adenylyl cyclase and requires STAT3 signaling

These findings have significant implications for inflammatory disease research, particularly for inflammatory bowel disease (IBD), where PTGIR, PTGER4, and calprotectin have all been implicated through genome-wide association studies (GWAS) . The established mechanistic link provides potential new therapeutic targets for modulating calprotectin levels, which serve as both biomarkers and mediators of inflammatory conditions.

What is the significance of PTGIR mutations in vascular pathologies?

Rare loss-of-function (LoF) mutations in PTGIR have been found to be enriched in patients with non-atherosclerotic arterial diseases, particularly fibromuscular dysplasia (FMD) and spontaneous coronary artery dissection (SCAD) . These conditions primarily affect middle-aged women and have previously had poorly understood pathophysiological mechanisms.

Through sequencing studies involving:

• 1071 unrelated FMD patients

• 363 SCAD patients

• Comparison with gnomAD v3 database (>30,000 individuals of European ancestry)

Researchers have identified a significant enrichment of rare PTGIR LoF variants in these patient populations, suggesting causal relationships between PTGIR dysfunction and these vascular pathologies. This connection provides new insights into the molecular mechanisms underlying these conditions and suggests potential therapeutic interventions targeting prostacyclin signaling pathways.

What are optimal approaches for measuring PTGIR receptor binding and function?

When studying PTGIR binding and function, researchers should consider multiple complementary approaches:

For binding affinity measurements:

• Human platelets provide a physiologically relevant system, with antagonist binding studies using RO1138452 and RO3244794 yielding pKi values of 9.3±0.1 and 7.7±0.03 respectively

• Recombinant expression systems using cell lines like CHO-K1 offer a controlled environment for binding studies, though affinity values may differ from native tissues (pKi values of 8.7±0.06 and 6.9±0.1 for the same compounds)

For functional assays:

• cAMP accumulation measurements in cells expressing human IP receptor (such as CHO-K1) provide direct assessment of receptor signaling, with functional antagonism showing pKi values of 9.0±0.06 and 8.5±0.11 for RO1138452 and RO3244794

• Validation with multiple agonists (such as carbaprostacyclin or Beraprost) and antagonists provides more robust functional characterization

Researchers should include appropriate positive and negative controls and consider the impact of receptor expression levels on apparent potency values.

What experimental approaches are effective for studying PTGIR's role in gene regulation?

Based on recent research demonstrating PTGIR's role in regulating calprotectin expression, several effective experimental approaches can be implemented:

• Genetic modulation of PTGIR expression:

  • Overexpression of PTGIR ORF in relevant cell lines (e.g., THP-1) resulted in significant increases in S100A8 and S100A9 expression

  • siRNA knockdown approaches achieving ~80% reduction in PTGIR expression produced ~50% reduction in S100A8/A9 expression

• Pharmacological manipulation:

  • Treatment with PTGIR agonist Beraprost induced S100A8/A9 expression (fold change 6.25-6.85, p < 0.001)

  • Treatment with antagonist RO1138452 decreased expression (fold change 0.46-0.48, p < 0.01)

  • Combination of genetic modulation and pharmacological treatments provides the most comprehensive assessment

• Protein quantification:

  • Measurement of both cellular and secreted calprotectin protein levels using ELISA (cell lysates showed fold change=6.7, p=0.00117; culture supernatants showed fold change=2.9, p=0.00111)

• Pathway analysis:

  • Investigation of downstream signaling components through inhibitor studies targeting adenylyl cyclase and STAT3 pathways

  • Analysis of transcription factor binding sites in promoter regions of regulated genes using resources like ENCODE ChIP-seq data

These multi-modal approaches provide complementary data for robust characterization of PTGIR's gene regulatory functions.

How should researchers approach PTGIR genetic variant identification and validation?

When investigating PTGIR genetic variants, particularly in disease contexts like FMD and SCAD, researchers should implement rigorous methodological approaches:

• Sequencing methodology:

  • Direct sequencing of PTGIR has been effectively employed in large cohorts (>1000 patients)

  • Both targeted resequencing and whole-genome/exome approaches have been utilized

  • Validation with Sanger sequencing for regions with low coverage (<10 reads) in next-generation sequencing data

• Control population selection:

  • Use of large reference databases like gnomAD v3 (>70,000 individuals) provides robust comparison groups

  • Selection of ethnically matched controls is critical for rare variant analysis

• Variant classification:

  • Focus on predicted loss-of-function variants for initial discovery

  • Implementation of gene-based burden testing using tools like TRAPD (Testing Rare vAriants using Public Data)

  • Statistical approach using two-sided Fisher's exact test for enrichment analysis

• Functional validation:

  • Expression of identified variants in appropriate cell systems

  • Assessment of signaling capacity through cAMP accumulation and downstream target gene expression

  • Protein stability and trafficking analysis for missense variants

These approaches ensure rigorous identification and characterization of disease-relevant PTGIR variants.

How does PTGIR interact with other prostanoid receptors in inflammatory signaling networks?

Current research is investigating the complex interplay between PTGIR and other prostanoid receptors, particularly PTGER4 (EP4). Both receptors have been implicated in inflammatory signaling and calprotectin regulation . Some key research findings and future directions include:

• PTGER4-specific agonists, like PTGIR agonists, increase calprotectin expression, suggesting convergent signaling pathways

• Both receptors utilize adenylyl cyclase and STAT3 signaling, raising questions about pathway cross-talk and synergy

• The distinct roles of these receptors in different cell types and inflammatory contexts remains incompletely understood

• Future research should investigate:

  • Temporal dynamics of receptor activation in inflammatory responses

  • Cell-type specific signaling differences

  • Compensatory mechanisms when either receptor is genetically or pharmacologically inhibited

  • Potential for combined modulation as therapeutic approaches

Understanding these complex signaling networks will provide more precise targets for anti-inflammatory therapeutics.

What emerging technologies could advance PTGIR research?

Several cutting-edge technologies hold promise for advancing PTGIR research:

• CRISPR-Cas9 gene editing:

  • Generation of cell lines with precise PTGIR mutations identified in vascular disorders

  • Creation of isogenic lines for controlled comparison of variant effects

  • Development of animal models with human PTGIR variants

• Single-cell transcriptomics:

  • Characterization of cell-specific PTGIR expression and signaling responses

  • Identification of heterogeneous responses within seemingly uniform cell populations

  • Mapping of PTGIR signaling networks across diverse tissue contexts

• Cryo-electron microscopy:

  • Determination of PTGIR structure in complex with agonists, antagonists, and G proteins

  • Insights into conformational changes during receptor activation

  • Structure-based design of more selective modulators

• Patient-derived iPSCs:

  • Generation of vascular cells from patients with PTGIR mutations

  • Functional characterization in disease-relevant cell types

  • Platform for personalized therapeutic screening

These technological approaches will enable more precise understanding of PTGIR biology and accelerate therapeutic development.

What are the most promising translational applications of PTGIR research?

Based on current understanding of PTGIR function and disease associations, several promising translational directions are emerging:

• Vascular disease biomarkers:

  • Assessment of PTGIR genetic variants as risk factors for FMD and SCAD

  • Development of screening protocols for high-risk individuals

  • Personalized prevention strategies based on PTGIR status

• Anti-inflammatory therapeutics:

  • Development of selective PTGIR modulators for inflammatory conditions

  • Targeting of the PTGIR-calprotectin axis in inflammatory bowel disease

  • Combined modulation of multiple prostanoid receptors for enhanced efficacy

• Pain management:

  • Optimization of PTGIR antagonists for pain control

  • RO1138452 and RO3244794 have demonstrated efficacy in reducing multiple pain modalities including inflammatory and chronic joint pain

  • Development of more selective compounds with improved pharmacokinetic properties

• Cardiovascular protection:

  • Exploration of PTGIR agonists for prevention of platelet aggregation and thrombosis

  • Tissue-specific targeting to minimize unwanted effects

  • Genetic risk stratification to identify patients most likely to benefit

These translational approaches represent the frontier of PTGIR research and highlight the clinical potential of targeting this receptor system.